BEAUTY HEALTH CO/THE (SKIN) Stock Price, Quote, News and Overview
NASDAQ:SKIN - Nasdaq - US88331L1089 - Common Stock - Currency: USD
SKIN Quote, Performance and Key Statistics
1.61
+0.01 (+0.63%)
The current stock price of SKIN is 1.61 USD. In the past month the price decreased by -4.73%. In the past year, price decreased by -45.05%.
SKIN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| UL | UNILEVER PLC-SPONSORED ADR | 23.29 | 138.82B | ||
| HLN | HALEON PLC-ADR | 23.44 | 45.58B | ||
| KVUE | KENVUE INC | 20.46 | 44.71B | ||
| EL | ESTEE LAUDER COMPANIES-CL A | 30.3 | 25.83B | ||
| BRBR | BELLRING BRANDS INC | 35.08 | 9.36B | ||
| COTY | COTY INC-CL A | 20.39 | 4.98B | ||
| IPAR | INTERPARFUMS INC | 28.81 | 4.30B | ||
| ELF | ELF BEAUTY INC | 23.86 | 4.23B | ||
| ODD | ODDITY TECH LTD-CL A | 22.92 | 2.51B | ||
| EPC | EDGEWELL PERSONAL CARE CO | 10.64 | 1.50B | ||
| OLPX | OLAPLEX HOLDINGS INC | 10.92 | 941.35M | ||
| HLF | HERBALIFE LTD | 4.24 | 837.56M |
Related stock screener links
About SKIN
Company Profile
The Beauty Health Co. engages in manufacturing and selling of serum-based hydradermabrasion systems and aesthetic products. The company is headquartered in Long Beach, California and currently employs 881 full-time employees. The company went IPO on 2020-02-10. The firm and its subsidiaries design, develop, manufacture, market, and sell esthetic technologies and products. The firm is personalizing skin health for all ages, genders, skin tones, and skin types. Its brands include Hydrafacial, SkinStylus and Keravive. Hydrafacial created the category of hydradermabrasion with its patented delivery system (Delivery System) that cleanses, extracts, and hydrates the skin with proprietary solutions and serums. SkinStylus specializes in microneedling with its products that are designed to provide a minimally-invasive microneedling skin treatment to help stimulate collagen and elastin production. Keravive specializes in scalp health with its products that are designed to cleanse, exfoliate, and hydrate the scalp and hair follicles. Hydrafacial's primary product offerings are the Syndeo device and its associated serum solutions and consumables.
Company Info
BEAUTY HEALTH CO/THE
2165 Spring Street
Long Beach CALIFORNIA 33139 US
CEO: Brenton L. Saunders
Employees: 881
Company Website: https://investors.beautyhealth.com/
Investor Relations: https://investors.beautyhealth.com/
Phone: 18006034996
BEAUTY HEALTH CO/THE / SKIN FAQ
What is the stock price of BEAUTY HEALTH CO/THE today?
The current stock price of SKIN is 1.61 USD. The price increased by 0.63% in the last trading session.
What is the ticker symbol for BEAUTY HEALTH CO/THE stock?
The exchange symbol of BEAUTY HEALTH CO/THE is SKIN and it is listed on the Nasdaq exchange.
On which exchange is SKIN stock listed?
SKIN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BEAUTY HEALTH CO/THE stock?
15 analysts have analysed SKIN and the average price target is 1.75 USD. This implies a price increase of 8.76% is expected in the next year compared to the current price of 1.61. Check the BEAUTY HEALTH CO/THE stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BEAUTY HEALTH CO/THE worth?
BEAUTY HEALTH CO/THE (SKIN) has a market capitalization of 199.83M USD. This makes SKIN a Micro Cap stock.
How many employees does BEAUTY HEALTH CO/THE have?
BEAUTY HEALTH CO/THE (SKIN) currently has 881 employees.
What are the support and resistance levels for BEAUTY HEALTH CO/THE (SKIN) stock?
BEAUTY HEALTH CO/THE (SKIN) has a support level at 1.54 and a resistance level at 1.61. Check the full technical report for a detailed analysis of SKIN support and resistance levels.
Is BEAUTY HEALTH CO/THE (SKIN) expected to grow?
The Revenue of BEAUTY HEALTH CO/THE (SKIN) is expected to decline by -15.56% in the next year. Check the estimates tab for more information on the SKIN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BEAUTY HEALTH CO/THE (SKIN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SKIN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SKIN, evaluating the profitability, health, valuation and growth aspects
- BEAUTY HEALTH CO/THE (SKIN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BEAUTY HEALTH CO/THE (SKIN) Sales and EPS estimates to see what analysts future expectations are.
- BEAUTY HEALTH CO/THE (SKIN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BEAUTY HEALTH CO/THE (SKIN) Insider and Institutional Ownership to learn about the owners and their transactions.
- BEAUTY HEALTH CO/THE (SKIN) Stock Chart to make your own analysis
- BEAUTY HEALTH CO/THE (SKIN) Latest news and press-releases to stay up to date.
Does BEAUTY HEALTH CO/THE (SKIN) stock pay dividends?
SKIN does not pay a dividend.
When does BEAUTY HEALTH CO/THE (SKIN) report earnings?
BEAUTY HEALTH CO/THE (SKIN) will report earnings on 2025-02-26, after the market close.
What is the Price/Earnings (PE) ratio of BEAUTY HEALTH CO/THE (SKIN)?
BEAUTY HEALTH CO/THE (SKIN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
What is the Short Interest ratio of BEAUTY HEALTH CO/THE (SKIN) stock?
The outstanding short interest for BEAUTY HEALTH CO/THE (SKIN) is 7.83% of its float. Check the ownership tab for more information on the SKIN short interest.
SKIN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to SKIN. When comparing the yearly performance of all stocks, SKIN is a bad performer in the overall market: 82.28% of all stocks are doing better.
SKIN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SKIN. While SKIN seems to be doing ok healthwise, there are quite some concerns on its profitability.
SKIN Financial Highlights
Over the last trailing twelve months SKIN reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS decreased by -160.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.03% | ||
| ROE | -47.17% | ||
| Debt/Equity | 9.23 |
SKIN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 49% to SKIN. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -259.37% and a revenue growth -15.56% for SKIN